Identification of cancer targets and therapeutics using phage display.
Phage display is a well-established approach for the identification of bioactive peptides and antibody fragments through the use of high diversity libraries. One major advantage of phage display lies in its ability to rapidly identify target-specific reagents with pharmacological activity as agonists or antagonists. Peptides and antibodies have several clinical advantages over traditional small-molecule chemotherapeutics, including specificity, selectivity and potency. Thus, phage display can be used to generate 'targeted therapeutics', which is the current clinical paradigm of choice in the field of oncology.
Brissette
Renee
R
Antyra Inc, 40 Talmadge Road, Edison, NJ 08818, USA. goldstein@antyra.com
Prendergast
John K A
JK
Goldstein
Neil I
NI
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001435:Bacteriophages / Q000235:genetics*; D006801:Humans; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D019151:Peptide Library
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D019151:Peptide Library